Unicycive Therapeutics (UNCY) Net Shares Issued and Repurchased (2023 - 2025)

Unicycive Therapeutics (UNCY) has reported Net Shares Issued and Repurchased for 3 consecutive years, with $669500.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Net Shares Issued and Repurchased fell 80.14% year-over-year to $669500.0; the trailing twelve-month figure through Dec 2025 stood at $669500.0 (down 80.14% YoY), and the FY2025 full-year result was $669500.0, down 80.14% from the prior year.
• Net Shares Issued and Repurchased advanced to $669500.0 in Q4 2025 per UNCY's latest filing, from $110000.0 in the prior quarter.
• Across five years, Net Shares Issued and Repurchased topped out at $9.0 million in Q4 2023 and bottomed at $19000.0 in Q1 2024.
• Historically, Net Shares Issued and Repurchased has averaged $2.6 million across 3 years, with a median of $669500.0 in 2025.
• The widest YoY moves for Net Shares Issued and Repurchased: up 478.95% in 2025, down 80.14% in 2025.
• Over 3 years, Net Shares Issued and Repurchased stood at $9.0 million in 2023, then plunged by 62.51% to $3.4 million in 2024, then slumped by 80.14% to $669500.0 in 2025.
• According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $669500.0, $110000.0, and $3.4 million for Q4 2025, Q1 2025, and Q4 2024 respectively.